Plantible | $30,000,000 | (Nov 19, 2024)
Theranautilus | $1,200,000 | (Nov 19, 2024)
Bluespine | $7,200,000 | (Nov 19, 2024)
Zenflow, Inc.
United States
- South San Francisco, CA
- 19/11/2024
- Series C
- $24,000,000
Forty million men in the US and over 500 million worldwide suffer from urinary obstruction related to benign prostatic hyperplasia (BPH). Millions of patients do not see effective relief from drugs, yet decline to undergo an invasive surgical procedure with high risk of side effects such as sexual dysfunction. To meet this clinical need, Zenflow has developed the Spring System. The device is designed to be deployed in the urologist's office in a simple, atraumatic procedure. Ongoing clinical trials have shown positive results out to four years after treatment.
- Industry Medical Equipment Manufacturing
- Website https://www.zenflow.com/
- LinkedIn https://www.linkedin.com/company/zenflowinc/
Related People
Shreya MehtaFounder
United States -
San Francisco, California
I am currently co-founder of Zenflow, a company focused on treating the life-altering symptoms associated with BPH, or enlarged prostate.
Specialties: Medtech innovation, Urology, Nephrology, Cardiac devices, Artificial Heart Valves, Ventricular Assist Devices, Pacemakers, Defibrillators, Stents
Coopah | $1,901,280 | (Nov 19, 2024)
Revisto | $4,000,000 | (Nov 19, 2024)
SuperAnnotate | $36,000,000 | (Nov 19, 2024)
IonKraft | $3,706,797 | (Nov 19, 2024)
ANELLO Photonics | Undisclosed Amount | (Nov 19, 2024)
Influur | $10,000,000 | (Nov 15, 2024)
Naturbeads | $9,890,632 | (Nov 15, 2024)